Print this page
-
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
- Mansi Shah MD (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Lymphoid Leukemia -
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones.
Protocol: 111804Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other
Any Site -
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.
Protocol: 011813Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia.
Protocol: 021808Principal Investigator:
- Dale Schaar M.D,Ph.D (Rutgers University)
Applicable Disease Sites: Leukemia, other